Anavex Life Sciences (AVXL) Reports Q3 Loss of $0.06/Share; No Longer Under SEC Investigation
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Anavex Life Sciences (NASDAQ: AVXL) reported Q3 EPS of ($0.06), versus ($0.22) reported last year.
The SEC staff recently advised Company’s legal counsel that the staff did not intend to recommend enforcement action by the Commission against the Company in connection with the investigation previously described in the Company’s 2015 Report on Form 10-K.
For earnings history and earnings-related data on Anavex Life Sciences (AVXL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Telesat Reports Preliminary Revenue Q3 of $235M
- Bovie Medical (BVX) Tops Q2 EPS by 2c
- Philip Morris (PM) Discloses Formal Probe Related to PM Thailand in 10-Q Filing
Create E-mail Alert Related CategoriesEarnings, Litigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!